目的 觀察升血小板膠囊聯(lián)合重組人血小板生成素注射液治療特發(fā)性血小板減少性紫癜（ITP）的臨床療效。方法 選取2016年1月-2016年10月在信陽市中心醫(yī)院住院治療的ITP患者68例，隨機分為對照組和治療組，每組各34例。對照組皮下注射重組人血小板生成素注射液，300 U/（kg·d），1次/d。治療組在對照組的基礎(chǔ)上口服升血小板膠囊，1.8 g/次，3次/d。兩組患者均治療14 d。評價兩組患者臨床療效，同時比較治療前后兩組患者血小板計數(shù)和血清相關(guān)血小板抗體（PAlgG）升高例數(shù)差異。結(jié)果 治療后，對照組臨床總有效率為70.59%，顯著低于治療組的91.18%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組血小板計數(shù)均明顯升高，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組患者血小板計數(shù)水平顯著高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，治療組血清PAIgG水平大于108 ng/10PA的例數(shù)顯著少于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 血小板膠囊聯(lián)合重組人血小板生成素能顯著縮短ITP患者血小板恢復的時間，提高臨床效果，具有一定的臨床推廣應用價值。

Objective To observe the effect of Shengxuexiaoban Capsules combined with Recombinant Human Thrombopoietin Injection in treatment of idiopathic thrombocytopenic purpura (ICP). Methods Patients (68 cases) with ICP in Xinyang Central Hospital from January 2016 to October 2016 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were subcutaneous injection administered with Recombinant Human Thrombopoietin Injection, 300 U/(kg·d), once daily. Patients in the treatment group were po administered with Shengxuexiaoban Capsules on the basis of the control group, 1.8 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, clinical efficacy was evaluated, and the difference of the platelet counts and the serum PalgG level in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 70.59%, which was significantly lower than 91.18% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the platelet counts in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the platelet counts in the treatment group were significantly higher than that in the control group, with significant difference between two groups (P<0.05). After treatment, the patients whose serum PalgG level more than 108 ng/10PA in the treatment group were significantly less than patients in the control group, with significant difference between two groups (P<0.05). Conclusion Shengxuexiaoban Capsules combined with Recombinant Human Thrombopoietin Injection can significantly shorten the recovery time of platelet in treatment of idiopathic thrombocytopenic purpura, and improve the clinical effect, which has a certain clinical application value.